Want to see UPC full AI Analyst Report?
Top Page
Universe Pharmaceuticals
(NASDAQ:UPC)
Select Model
Select Model
Rating:39Underperform
Price Target:
$3.00
▼(-11.50% Downside)
Action:Downgraded
Date:08/01/26
Universe Pharmaceuticals receives a low overall score due to persistent financial challenges: declining revenue, negative cash flow, and lack of profitability. The bearish technical picture and unfavorable valuation further weigh on the stock. While the balance sheet provides some stability with low leverage, these strengths are insufficient to offset the fundamental weaknesses. The stock is considered high risk.
Positive Factors
Conservative leverage / manageable balance sheet
Low debt relative to equity and modest total borrowings provide structural financial flexibility. Manageable leverage reduces near-term solvency risk and preserves capacity to fund R&D or bridge losses via borrowing if needed, making the balance sheet a durable stabilizer while operations recover.
Negative Factors
Multi-year revenue decline
Sustained, material top-line contraction erodes scale economics and market position. Reduced revenue weakens pricing power, increases per-unit fixed costs and makes it harder to leverage margin improvements; without a reversal, long-term viability and investment returns are at greater risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative leverage / manageable balance sheet
Low debt relative to equity and modest total borrowings provide structural financial flexibility. Manageable leverage reduces near-term solvency risk and preserves capacity to fund R&D or bridge losses via borrowing if needed, making the balance sheet a durable stabilizer while operations recover.
Read all positive factors
Universe Pharmaceuticals (UPC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.00M
Dividend YieldN/A
Average Volume (3M)955.25K
Price to Earnings (P/E)―
Beta (1Y)1.91
Revenue Growth-8.04%
EPS Growth-100.01%
CountryUS
Employees216
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding631,761
10 Day Avg. Volume2,486,504
30 Day Avg. Volume955,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00082
P/FCF Ratio>-0.01
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Universe Pharmaceuticals Business Overview & Revenue Model
Company Description
Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These ...
How the Company Makes Money
null...
Universe Pharmaceuticals Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
55
Neutral
Cash Flow
25
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.74M | 17.86M | 23.02M | 32.31M | 40.14M | 47.98M |
| Gross Profit | 6.36M | 6.30M | 6.07M | 10.32M | 21.89M | 25.33M |
| EBITDA | -1.31M | -2.92M | -7.36M | -3.18M | -6.40M | 14.20M |
| Net Income | -1.94M | -3.67M | -8.73M | -6.16M | -8.74M | 11.32M |
Balance Sheet | ||||||
| Total Assets | 71.47M | 69.30M | 67.95M | 53.29M | 59.54M | 70.14M |
| Cash, Cash Equivalents and Short-Term Investments | 29.05M | 33.59M | 29.50M | 18.50M | 18.86M | 21.80M |
| Total Debt | 9.55M | 9.26M | 7.99M | 5.48M | 3.94M | 4.33M |
| Total Liabilities | 15.82M | 13.17M | 22.45M | 13.75M | 13.10M | 11.21M |
| Stockholders Equity | 55.65M | 56.13M | 45.50M | 39.53M | 46.44M | 58.93M |
Cash Flow | ||||||
| Free Cash Flow | -12.39M | -5.40M | -9.87M | 1.08M | -1.41M | -15.59M |
| Operating Cash Flow | -11.91M | -5.05M | -9.51M | 1.12M | -1.31M | -2.06M |
| Investing Cash Flow | -2.02M | -341.81K | -361.29K | -44.17K | -3.91M | -27.06M |
| Financing Cash Flow | -6.82M | 9.73M | 33.95M | -1.39M | 3.32M | 26.58M |
Universe Pharmaceuticals Technical Analysis
Negative
3.39
Price Trends
3.97
Negative
3.41
Negative
3.69
Negative
Market Momentum
-0.08
Positive
42.87
Neutral
7.69
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UPC, the sentiment is Negative. The current price of 3.39 is below the 20-day moving average (MA) of 4.40, below the 50-day MA of 3.97, and below the 200-day MA of 3.69, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 42.87 is Neutral, neither overbought nor oversold. The STOCH value of 7.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UPC.
Universe Pharmaceuticals Risk Analysis
Universe Pharmaceuticals disclosed 69 risk factors in its most recent earnings report. Universe Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Universe Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $47.75M | -1.34 | -18.98% | ― | -7.07% | 75.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | $3.04M | -0.03 | -56.96% | ― | ― | ― | |
39 Underperform | $2.00M | -0.92 | -6.60% | ― | -8.04% | -100.01% | |
39 Underperform | $3.95M | -0.33 | 5740.28% | ― | ― | ― | |
32 Underperform | $2.42M | -0.06 | -408.33% | ― | ― | 92.53% |
* Healthcare Sector Average
UPC
Universe Pharmaceuticals
3.16
-0.51
-13.90%
CPHI
China Pharma Holdings
1.11
-0.49
-30.62%
RDHL
RedHill Biopharma
0.65
-0.55
-45.83%
SXTC
China SXT Pharmaceuticals
0.06
-236.94
-99.97%
PRFX
PainReform
1.00
-5.74
-85.17%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
3.80
-32.50
-89.53%
Universe Pharmaceuticals Corporate Events
Universe Pharmaceuticals Closes Patent-Rich Acquisition of Best Praise International Limited
Jul 31, 2026
On June 30, 2026, Universe Pharmaceuticals completed the acquisition of Best Praise International Limited, a company that holds five patents in China for pharmaceutical compounds and drug delivery technologies targeting age-related, neurodegenerat...
Universe Pharmaceuticals Reports Interim Results and Capital Structure Changes for Six Months Ended March 31, 2026
Jul 29, 2026
Universe Pharmaceuticals Inc. is a China-based pharmaceutical manufacturer and distributor headquartered in Ji’an, Jiangxi, that serves both domestic and international markets as a foreign private issuer listed in the U.S. Its operations are...
Universe Pharmaceuticals Moves to Acquire Best Praise Patents in All-Stock Deal
Jun 26, 2026
On June 17, 2026, Universe Pharmaceuticals Inc. entered into a share purchase agreement to acquire 100% of Best Praise International Limited, which holds five early-stage pharmaceutical patents in China spanning age-related diseases, neurodegenera...
Universe Pharmaceuticals Grants CEO Majority-Strengthening Equity Award Under 2026 Plan
May 14, 2026
Universe Pharmaceuticals Inc. disclosed that on April 14, 2026 it adopted a 2026 Equity Incentive Plan authorizing up to 84,500 ordinary shares for equity-based compensation awards. The plan covers both Class A and Class B ordinary shares and is i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.